Address
Laboratory Representative
(P)
Description
The U.S. Army Medical Research and Development Command (USAMRDC) is the Army's medical materiel developer. The Command has four major Core Capabilities:
-
Shape future medical solutions through research, advanced technology, and partnerships;
- Execute streamlined medical logistics, facilities and acquisition management;
- Develop, integrate, acquire and sustain medical IM/IT solutions; and
- Provide best business and program management solutions.
Mission
The USAMRDC is the executive or lead agency responsible for:
- Military Human Immunodeficiency Virus (HIV) R&D Program (Acquired Immune Deficiency Syndrome (AIDS))
- Military Infectious Diseases Research Program (MIDRP)
- Global Emerging Infections Surveillance and Response System (GEIS)
- Use of Investigational New Drugs for Force Health Protection
- DOD Food and Nutrition Research, Development, Test, Evaluation, and Engineering Program
- Combat Dentistry Research Program
- Gulf War Illnesses/Force Health Protection Research Program
- Peer Reviewed Medical Research Program (PRMRP)
The USAMRDC's expertise in these critical areas helps establish and maintain the capabilities required by the Army to fight and win on the battlefield.
Technology Disciplines
U.S. Army Medical Research and Development Command seeks additional licensees for the Body Cooling System; a lightweight portable apparatus that reduces a person's core temperature by transferring heat through the hands and forearm into cold water.
The Body Cooling System can be used in high risk heat environments to decrease the incidence of heat-related illnesses by reducing the body’s core temperature, therefore extending heat tolerance and increasing total work time. It is ideal for local and professional sports teams, athletic/endurance events such as marathons, training situations, firefighting, and any strenuous activity commonly performed in hot environments.
• Minimizes heat-related illnesses (Exertional Heat Stroke is usually among the top 3 causes of death in athletes)
• Allows for easy transportation, setup, and storage
• Accommodates 6 adults at a time
• Integrated thermometer monitors water temperature
• Assembly and use instructions stenciled on the waterproof, flexible fabric
• Holds up to 48 gallons of water, equaling 6 inches of water in the reservoir
• Legs adjust to provide ideal height for users
• Inexpensive to manufacture
• Successfully implemented in military settings
| Patent Number | US 10,058,448 |
| Patent Issue Date | Aug 28, 2018 |
The U.S. Army seeks patent licensees for an antimicrobial decapeptide system that augments our natural immune responses to prevent and disrupt biofilm formation. This invention is especially well suited for the prevention and treatment of plaque-related oral diseases. In Phase 2a clinical trials Plaktak™ gum demonstrated safety and efficacy against plaque after 2-4 weeks of treatment in people with gingivitis.
Background & Technology
- KSL-W is a member of a decapeptide family with demonstrated effectiveness to prevent biofilm formation on teeth, inhibit the growth of oral microorganisms, and reduce the development of plaque. KSL-W mimics the body’s own defense system – namely it exhibits selective toxicity for prokaryotes. The result is efficacy against supragingival plaque bacteria, but little effect on normal oral flora and low potential for drug resistance. KSL–W is readily adsorbed to tooth-like materials and effectively desorbed over time; this peptide also has good stability in saliva. The U.S. Army has formulated this peptide into an antiplaque chewing gum (Plaktak™) for sustained and improved delivery in the mouth. KSL-W readily degrades in gastro-intestinal environments causing no harm to the intestinal flora. Double-blind, randomized, controlled, dose escalation clinical trials of Plaktak™ demonstrated:
- Phase 1 single dose safety and tolerability, and
- Phase 2a multiple doses safety, tolerability, and proof of concept efficacy against plaque after
- 2-4 weeks of active treatment in a gingivitis population.
- No serious adverse events occurred in both single and multiple doses trials.
| Patent Status | • U.S. patents 8,778,889 and 7,494,980 – compositions and uses beyond chewing gum • Numerous peer-reviewed articles |
| Patent Number | 8,778,889 and 7,494,980 |
| Patent Issue Date | Dec 03, 2019 |
EC Temp utilizes a mathematical process to calculate the change in core body temperature based on heart rate time series data. No temperature sensor is needed. Talk to licensing agent [email protected] if thermoregulation, core body temperature, heat illness and performance enhancement technologies matter to you. EC Temp utilizes a mathematical process to calculate the change in core body temperature based on heart rate time series data.
Heat stroke is one of the most preventable deaths in our athletic population. Field testing has demonstrated accurate temperature estimates using ECTemp even when operated 24/7 for several days. With this new capability, an athlete or worker can be alerted if and when a predicted core body temperature exceeds a predetermined threshold, thus avoiding potential heat illness or undue stress that would impact future performance.
Easy to implement algorithm can be incorporated in commercial heart rate monitors to provide a value added feature in the otherwise crowded market; Provides valuable data to help athletes, coaches, workers, and supervisors optimize performance and better manage work-rest cycles; Core body temperature can be displayed in real time on many devices, such as wrist worn displays, smartphones, or heads up displays; Can be used during activity for real-time data and/or post activity for analysis.
| Patent Number | US Patent Application No. 15/449,943 |
| Inventors | Mark J. Buller |
| Patent Issue Date | Sep 13, 2019 |
The current prototype includes an acuity task, contrast sensitivity task, glare discomfort task, and target detection task. The prototype device was designed for testing the impact of various glare conditions on healthy subjects. Talk to licensing agent [email protected] if vision and performance enhancement and technologies matter to you.
The Glare Testing Device measures visual performance and discomfort under various glare conditions. The invention includes broader applications. For example, it could be used to identify pre‐cataract glare related issues which would warrant intraocular lens surgery. The device could be useful in investigating the side‐effects of refractive surgical procedures and identifying suitable candidates for different refractive surgeries. It also could be useful in identifying glare‐related performance issues in drivers and pilots, both for civilian and military screening and licensing procedures.
• Prototype device in use at Army Aeromedical Research Laboratory to collect data for medical/performance research;
• Potential use in testing sunglasses or other means of reducing glare and improving visual acuity;
• Device can be designed in desktop or portable form.
| Technology Types | Athletic & Performance Enhancing |
| Patent Status | Provisional |
| Patent Number | US Provisional 62/808,963 |
| Inventors | Kevin J. O'Brien, Victor A. Estes |
| Patent Issue Date | Feb 22, 2019 |
This smartphone app uses sleep-wake history and caffeine consumption along with measurements of past performance as inputs to predict future alertness and cognitive performance levels. If sleep, alertness and performance enhancement technologies matter to you, contact licensing agent [email protected].
Sleep loss impairs alertness and cognitive performance. 2B-Alert Smartphone App is fully functional software available to companies that want to incorporate this app into their software product. Past and current performance are measured using a psychomotor vigilance task (PVT) test for accurate, objective assessment.
The system’s user-friendly interface allows for user evaluation of the effects of caffeine consumption and/or nap schedules to optimize future performance at the desired times. The app includes a visual reaction time PVT test, which is the gold standard for estimating cognitive performance. An intuitive graphical user interface allows the user and, if desired, others such as a supervisor or safety officer, to view predicted cognitive performance levels at desired future times.
User-friendly, intuitive software available for transfer to a commercial partner; Built-in PVT test for accurate, objective assessment of current alertness; User can identify schedule of caffeine and/or nap to achieve peak alertness and cognitive performance at desired time; Includes a caffeine optimization algorithm
| Patent Number | Serial No. 15/580,907 |
| Inventors | Jaques Reifman; Maxim Y. Khitrov Jianbo Liu; Nancy Wesensten; Thomas Balkin; Sridhar Ramakrishnan |
| Patent Issue Date | Dec 08, 2017 |
Evaluating new protective equipment such as eyewear and face shields will benefit from this technology. The Surrogate Human Eye Model prototype was initially designed for testing responses to ocular trauma with or without protective eyewear. Contact licensing agent [email protected] if vision and performance enhancement technologies matter to you.
The USAARL eye model is based on a hydrogel matrix which can be modified to a required specification. The eye model begins as porcine gelatin mixed with a calcium chloride solution injected into silicone molds of the internal volume of the human eye and optic nerve. After demolding, they are submerged in a sodium alginate solution. Hybridized hydrogels can be made by the addition of other crosslinked polymers, but it is the calcium crosslinked alginate matrix that defines the form. Completed eye models are stored at 5o C or used immediately.
Anatomical and Biological accurate model of the human eye; • Standardized, storable and economical replacement of current animal post-mortem ocular tissue; • Hydrogel-based materials can be adapted for biomedical testing, training, and tissue replacement or wound repair; Modular eye model hydrogel-matrix design(s); • Accuracy in artifact placement for use in medical simulation training using high-frequency ultrasound; Platform for tissue culture and chemical testing;• Model for developing advance protective eyewear and face shields
| Patent Number | US Provisional 62/719,446 |
| Inventors | Michael K. Smolek |
| Patent Issue Date | Aug 17, 2019 |
